Business Wire

Galderma Launches Alastin®in China, Supporting the Skin’s Natural Regenerative Abilities in a Rapidly Expanding Market

Share

Galderma marks the 10th anniversary of its premium medical skincare brand Alastin with the launch of four core products in China, each formulated to support the skin’s natural regenerative abilities to help with skin recovery before and after aesthetic procedures1,2 This is the first launch to feature Alastin’s new packaging and builds on its strong growth in key markets including the United States, Canada, and the United Kingdom As the demand for perioperative skincare accelerates, this expansion shows Galderma’s commitment to delivering science-backed products that drive superior outcomes for even more patients3-6

Galderma (SIX: GALD) today announced the launch of four core Alastin® products in China, marking the premium medical skincare brand’s debut in one of the world’s fastest growing aesthetic skincare markets.6-8 This is the first launch to feature Alastin by Galderma’s new re-energized, premium look and feel, a bold evolution that reflects its leadership in perioperative skincare.

Alastin offers full-spectrum care for patients undergoing aesthetic procedures, from pre-treatment preparation to post-treatment recovery and at-home maintenance, supporting the skin’s natural regenerative abilities to improve overall skincare results.1,2,9-13 With over 50 global dermatological publications and 22 patents, Alastin is strongly backed by science and is the number one peri-procedural skincare brand in the United States.14-16 This launch follows the strong growth of Alastin in other key markets and demonstrates Galderma’s commitment to addressing the needs of patients with science-backed solutions.

“With Alastin by Galderma, we have a comprehensive perioperative solution to enhance skin recovery around aesthetic treatment and maintenance programs that bring together Galderma’s leading expertise in Dermatological Skincare and Injectable Aesthetics. As the Asia-Pacific region’s beauty and aesthetics market continues to grow at pace, we’re proud to bring Alastin to patients in China who are seeking advanced solutions to support them in their aesthetic journeys.”

ALAN D. WIDGEROW, MBBCH, MMED, FCS, FACS
CHIEF SCIENTIFIC OFFICER GALDERMA, HEAD SKIN SCIENCE
CENTER FOR INNOVATION, HEAD ALASTIN INNOVATIONS 

Comprehensive perioperative solutions addressing growing needs

Four core Alastin products that cover all stages of the aesthetic treatment process will now be available in China, creating an integrated in-clinic and at-home skincare program:

  • Regenerating Skin Nectar to optimize visible treatment results9
  • HA (Hyaluronic Acid) IMMERSE Serum™ to hydrate and support skin barrier repair10
  • INhance Serum helps to enable quicker recovery after treatment with injectables, improving the appearance of the skin post-injection11
  • Restorative Skin Complex to support aesthetic treatment results by helping to reduce the visible signs of aging12

This comprehensive perioperative series of regenerative skincare products advances aesthetic treatments from isolated procedures to full-spectrum management.1,2,9-12 It reflects Galderma’s holistic approach to aesthetic care – working across its Dermatological Skincare and Injectable Aesthetics portfolios to ensure that products complement each other, delivering seamless, science-backed solutions that elevate patient outcomes.1,2,9-13 Select products are powered by proprietary TriHex Technology® to further enhance skin regeneration and recovery.1,2,13

China’s medical aesthetics market is experiencing remarkable growth, and is projected to increase by up to 15% in the next decade.17 As aesthetic treatments become increasingly mainstream there is rising demand for perioperative skincare, with consumers willing to invest in advanced technologies and premium products to achieve optimal aesthetic outcomes.3-6,17 With its proven efficacy and full-spectrum approach to pre- and post-procedure care, as well as at-home maintenance, Alastin by Galderma is uniquely positioned to address this need.1,2,6-9

 “We’re seeing an incredible rise in demand for aesthetic procedures in China, and with that comes a growing need for effective perioperative skincare. Alastin by Galderma brings a scientifically advanced approach to skin recovery, and I’m excited to see Chinese patients gain access to products that can truly support their skin before and after treatment, and elevate their overall results.”

PROFESSOR YANG BIN
DERMATOLOGY HOSPITAL OF SOUTHERN MEDICAL UNIVERSITY
CHINA

This launch marks ten years of pioneering innovation with Alastin, demonstrating Galderma’s commitment to purposeful growth with the brand’s refreshed premium look and feel, and entry into one of the fastest growing aesthetic skincare markets. Following strong growth in North America, Latin America, Australia, and the U.K. & Ireland, Alastin is now undergoing rapid international expansion, offering its premium products to even more patients. By identifying emerging patient needs and delivering science-backed solutions, Galderma continues to shape the future of dermatology and elevate outcomes across the aesthetic journey.

About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

References

1.

Widgerow AD, et al. Extracellular Matrix Modulation: Optimizing Skin Care and Rejuvenation Procedures. J Drugs Dermaol. 2016;15(Suppl 4):s63–71.

2.

Widgerow AD, et al. Preoperative Skin Conditioning: Extracellular Matrix Clearance and Skin Bed Preparation, A New Paradigm. Aesthetic Surgery Journal 2019;39(Suppl 3):s103–11. doi:10.1093/asj/sjz022

3.

Guidepoint Qsight. From Gen Z to GLP-1s: Trends Reshaping the Medical Aesthetics Industry. Accessed September 2025. Available online.

4.

Verified Market Reports. Preoperative Skin Preparation Market. Accessed September 2025. Available online.

5.

PW Consulting Health Care Research Center. Post Procedure Skin Care Product Market. Accessed September 2025. Available online.

6.

Kwon SH, et al. Experiences and attitudes toward aesthetic procedures in East Asia: a cross-sectional survey of five geographical regions. Arch Plast Surg. 2021;48(6):660-669. doi: 10.5999/aps.2020.02565.

7.

Fortune Business Insights. China Skincare Market Size, Share & Industry Analysis. Accessed September 2025. Available online.

8.

Mordor Intelligence. China Cosmetic Products Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030). Accessed September 2025. Available online.

9.

Alastin. Regenerating Skin Nectar with TriHex Technology®. Accessed September 2025. Available online.

10.

Alastin. HA (Hyaluronic Acid) IMMERSE Serum™. Accessed September 2025. Available online.

11.

Alastin. INhance Post-Injection Serum with TriHex Technology®. Accessed September 2025. Available online.

12.

Alastin. Restorative Skin Complex with TriHex Technology®. Accessed September 2025. Available online.

13.

Lee WW, et al. A Multi-Center Evaluation of Restorative Eye Treatment and INhance With Trihex Technology to Improve Aesthetic Outcomes When Used Pre- and Post-Blepharoplasty. Aesthet Surg J Open Forum. 2022 Dec 14;5:ojac089. doi: 10.1093/asjof/ojac089.

14.

Galderma. Data on File. Alastin Publication List.

15.

Galderma. Data on File. Alastin Patent List.

16.

Galderma. Data on File. LifeSci Consulting Primary Market Research. 2022.

17.

Chameleon Pharma. China’s Dynamic Aesthetic Medicine Market: Outlook, Trends, and Opportunities. Accessed September 2025. Available online.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250909403223/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

TON Strategy Company Welcomes $TON Trading on Gemini, Robinhood, and Zengo, as Ecosystem Momentum Builds10.9.2025 14:00:00 CEST | Press release

$TON now live on three leading digital asset platforms serving U.S. and global retail investors Listings expand availability of $TON beyond institutions, enabling mainstream adoption News follows TON Strategy Company’s own momentum, including its $558M PIPE and up to $250M buyback program launch TON Strategy Company (Nasdaq: TONX) (the “Company”), a digital asset treasury company committed to holding Toncoin ($TON), today celebrated the launch of $TON trading on Gemini, Robinhood, and Zengo. The listings expand access to one of the top 25 cryptocurrencies by market capitalization. “Today marks an important moment for the TON ecosystem, with $TON now more accessible to millions of investors through three widely used platforms,” said Manuel Stotz, Executive Chairman of TON Strategy Company. “These listings serve as a powerful indicator of the growing recognition of $TON’s utility and relevance – and reinforces our conviction as a contributor to network stability. I expect increased acces

Taktile Unveils AI Agents Enabling Banks to Process 5x More SMB Loans Without Extra Headcount10.9.2025 14:00:00 CEST | Press release

Taktile, the AI Decision Platform for financial services, today announced the launch of its fully customizable AI agents, a capability designed to transform how financial institutions perform credit underwriting. For years, underwriting teams have been constrained by manual document reviews, scattered data, and growing backlogs. With Taktile’s customizable AI agents, SMB lenders can now process 5x more loans without adding headcount – eliminating bottlenecks and freeing underwriters to focus on high-value, strategic decisions. “Credit teams don’t need another AI tool that adds complexity – they need a workforce multiplier,” said Maximilian Eber, Co-Founder and CPTO of Taktile. “With Taktile’s customizable AI agents, teams can automate the repetitive tasks that overwhelm them, while maintaining the accuracy, transparency, and human oversight required in financial services. What makes this truly different is that these agents are not one-size-fits-all – they are fully customizable bluepr

Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the European Association of Dermatology and Venerology 2025 Congress10.9.2025 13:30:00 CEST | Press release

- 24-week data from the Phase 3 STOP-HS clinical trial program of povorcitinib in patients with hidradenitis suppurativa (HS) selected as a late-breaking oral presentation Today Incyte (Nasdaq:INCY) announced that it will present new data from its dermatology portfolio at the European Association of Dermatology and Venerology (EADV) 2025 Congress, held from September 17 – 20, in Paris. Highlights include late-breaking, oral and poster presentations featuring data for povorcitinib (INCB054707), an oral small-molecule JAK1 inhibitor, and ruxolitinib cream (Opzelura®), a topical JAK1/2 inhibitor. “Our presence at EADV demonstrates the significant progress across our dermatology portfolio. The late-breaking data from the STOP-HS clinical trial program reinforce the potential of povorcitinib to benefit patients impacted by hidradenitis suppurativa (HS), a challenging and debilitating immune-mediated dermatologic condition,” said Pablo J. Cagnoni, M.D., President and Head of Research and Dev

PsiQuantum Raises $1 Billion to Build Million-Qubit Scale, Fault-Tolerant Quantum Computers10.9.2025 13:00:00 CEST | Press release

PsiQuantum also announces collaboration with NVIDIA to accelerate quantum computing development PsiQuantum today announced it has raised $1 billion in funding for its Series E round to build the world’s first commercially useful, fault-tolerant quantum computers. This funding will equip the company to break ground on utility-scale quantum computing sites in Brisbane and Chicago, deploy large-scale prototype systems to validate systems architecture and integration, and further advance the performance of its quantum photonic chips and fault-tolerant architecture. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250910135739/en/ Omega, PsiQuantum’s silicon photonic quantum chipset, designed by PsiQuantum and manufactured at GlobalFoundries’ Fab 8 in New York. Led by funds and accounts managed by affiliates of BlackRock, along with Temasek and Baillie Gifford, this fundraising values the company at $7 billion and brings in new inv

Earnix Delivers on Promise of AI with Intelligent Decisioning Platform10.9.2025 13:00:00 CEST | Press release

The company’s new AI-enabled solutions enable carriers to improve operations, foster innovation and enhance customer experiences At its Excelerate 2025 conference, Earnix, the leader in Dynamic AI for insurance, announced a new suite of solutions designed to help insurers fully realise the promise of AI. Built specifically for the insurance industry, these technologies accelerate decision-making and improve personalised customer experiences all while ensuring compliance in complex regulatory environments. For insurers, these Intelligent Decisioning capabilities unlock smarter, data-driven decision-making at scale. The platform delivers real-time insights and personalised offerings with faster speed-to-market, while maintaining robust governance of automated decisions. Customers benefit from: Improved profitability and risk management Stronger regulatory compliance and governance Enhanced customer satisfaction through personalised engagement Greater competitive positioning in a rapidly

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye